MOORE JOHN R 4
4 · Edgewise Therapeutics, Inc. · Filed Sep 24, 2024
Insider Transaction Report
Form 4
MOORE JOHN R
General Counsel
Transactions
- Exercise/Conversion
Common Stock
2024-09-20$0.71/sh+50,000$35,500→ 53,252 total - Exercise/Conversion
Common Stock
2024-09-23$0.71/sh+20,922$14,855→ 24,174 total - Sale
Common Stock
2024-09-20$28.37/sh−50,000$1,418,510→ 3,252 total - Sale
Common Stock
2024-09-23$27.63/sh−20,922$578,064→ 3,252 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-09-23−20,922→ 41,636 totalExercise: $0.71Exp: 2030-09-01→ Common Stock (20,922 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-09-20−50,000→ 62,558 totalExercise: $0.71Exp: 2030-09-01→ Common Stock (50,000 underlying)
Footnotes (1)
- [F1]1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.